KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Elevance Health (ELV) EBITDA (2016 - 2025)

Elevance Health (ELV) has disclosed EBITDA for 17 consecutive years, with $1.4 billion as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 104.45% to $1.4 billion in Q3 2025 year-over-year; TTM through Sep 2025 was -$59.0 million, a 101.0% decrease, with the full-year FY2024 number at $2.1 billion, up 12.38% from a year prior.
  • EBITDA was $1.4 billion for Q3 2025 at Elevance Health, up from -$3.0 billion in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $33.7 billion in Q4 2023 to a low of -$43.9 billion in Q4 2021.
  • A 5-year average of -$8.1 billion and a median of -$1.2 billion in 2021 define the central range for EBITDA.
  • Biggest YoY gain for EBITDA was 211.84% in 2023; the steepest drop was 9613.39% in 2023.
  • Elevance Health's EBITDA stood at -$43.9 billion in 2021, then soared by 31.2% to -$30.2 billion in 2022, then surged by 211.84% to $33.7 billion in 2023, then tumbled by 97.2% to $946.0 million in 2024, then skyrocketed by 48.63% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ELV's EBITDA are $1.4 billion (Q3 2025), -$3.0 billion (Q2 2025), and $590.0 million (Q1 2025).